A systematic literature review identifying associations between outcomes and quality of life (QoL) or healthcare resource utilization (HCRU) in schizophrenia

References

• Reichenberg A, Harvey PD, Bowie CR, et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr Bull. 2009;35:1022–1029.
   PubMed Web of Science ®Google Scholar
• Martin P, Caci H, Azorin JM, et al. [A new patient focused scale for measuring quality of life in schizophrenic patients: the Schizophrenia Quality of Life Scale (SOL)]. Encephale. 2005;31:559–566.
   PubMed Web of Science ®Google Scholar
• Nemade R, Dombeck M. Schizophrenia symptoms, patterns, statistics and patters 2009 [updated 2017 Dec 19]. Available from: www.mentalhelp.net/poc/view_doc.php?type=doc&id=8805
   Google Scholar
• Abouzaid S, Jutkowitz E, Foley KA, et al. Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia. Popul Health Manag. 2010;13:247–254.
   PubMed Web of Science ®Google Scholar
• Willis M, Svensson M, Lothgren M, et al. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11:585–594.
   PubMed Web of Science ®Google Scholar
• de Silva J, Hanwella R, de Silva VA. Direct and indirect cost of schizophrenia in outpatients treated in a tertiary care psychiatry unit. Ceylon Med J. 2012;57:14–18.
   PubMedGoogle Scholar
• Voruganti LN, Awad AG, Oyewumi LK, et al. Assessing health utilities in schizophrenia. A feasibility study. Pharmacoeconomics. 2000;17:273–286.
   PubMed Web of Science ®Google Scholar
• Millier A, Schmidt U, Angermeyer MC, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014;54:85–93.
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877–893.
   PubMed Web of Science ®Google Scholar
• Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90:162–173.
   PubMed Web of Science ®Google Scholar
• Brain C, Kymes S, DiBenedetti DB, et al. Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study. BMC Psychiatry. 2018;18:253.
   PubMed Web of Science ®Google Scholar
• Shamsaei F, Cheraghi F, Bashirian S. Burden on family caregivers caring for patients with schizophrenia. Iran J Psychiatry. 2015;10:239–245.
   PubMedGoogle Scholar
• Nanko S, Moridaira J. Reproductive rates in schizophrenic outpatients. Acta Psychiatr Scand. 1993;87:400–404.
   PubMed Web of Science ®Google Scholar
• Schomerus G, Schwahn C, Holzinger A, et al. Evolution of public attitudes about mental illness: a systematic review and meta-analysis. Acta Psychiatr Scand. 2012;125:440–452.
   PubMed Web of Science ®Google Scholar
• Winklbaur B, Ebner N, Sachs G, et al. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci. 2006;8:37–43.
   PubMedGoogle Scholar
• O’Day K, Rajagopalan K, Meyer K, et al. Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US. Clinicoecon Outcomes Res. 2013;5:459–470.
   PubMedGoogle Scholar
• Graham CN, Mauskopf JA, Lawson AH, et al. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012;15:55–64.
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7:4.
   PubMedGoogle Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
   Google Scholar
• Iancu I, Poreh A, Lehman B, et al. The Positive and Negative Symptoms Questionnaire: a self-report scale in schizophrenia. Compr Psychiatry. 2005;46:61–66.
   PubMed Web of Science ®Google Scholar
• William G. Clinical global impressions. ECDEU assessment manual for psychopharmacology—Revised. Rockville, MD: U.S. Department of Health, Education, and Welfare; Public Health Service, Alcohol; Drug Abuse, and Mental Health Administration: National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Research Programs; 1976; p. 218–222. OCLC 2344751. DHEW Publ No ADM 76–338 – via Internet Archive.
   Google Scholar
• Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item Negative Symptom Assessment. J Psychiatr Res. 1993;27:253–258.
   PubMed Web of Science ®Google Scholar
• Beck AT, Baruch E, Balter JM, et al. A new instrument for measuring insight: the Beck Cognitive Insight Scale. Schizophr Res. 2004;68:319–329.
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571.
   PubMed Web of Science ®Google Scholar
• Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166:650–653.
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Lewander T, Malm U, et al. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2001;55 :5–69.
   PubMed Web of Science ®Google Scholar
• Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766–771.
   PubMed Web of Science ®Google Scholar
• Birchwood M, Smith J, Cochrane R, et al. The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br J Psychiatry. 1990;157:853–859.
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101:323–329.
   PubMed Web of Science ®Google Scholar
• Ustun TB, Chatterji S, Kostanjsek N, et al. Developing the World Health Organization Disability Assessment Schedule 2.0. Bull WHO. 2010;88:815–823.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365.
   PubMed Web of Science ®Google Scholar
• Potkin S B-KD, Edgar C, Luo S. PRM30 evaluating readiness for work in patients with schizophrenia: “The Readiness for Work Questionnaire” (WoRQ). Value Health. 2012:15;A650.
   PubMed Web of Science ®Google Scholar
• Kemp R, Kirov G, Everitt B, et al. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry. 1998;172:413–419.
   PubMed Web of Science ®Google Scholar
• Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241–247.
   PubMed Web of Science ®Google Scholar
• Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177–183.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.
   PubMed Web of Science ®Google Scholar
• Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010;118:271–278.
   PubMed Web of Science ®Google Scholar
• Levene JE, Lancee WJ, Seeman MV. The perceived family burden scale: measurement and validation. Schizophr Res. 1996;22:151–157.
   PubMed Web of Science ®Google Scholar
• Richieri R, Boyer L, Reine G, et al. The Schizophrenia Caregiver Quality of Life questionnaire (S-CGQoL): development and validation of an instrument to measure quality of life of caregivers of individuals with schizophrenia. Schizophr Res. 2011;126:192–201.
   PubMed Web of Science ®Google Scholar
• EuroQol G. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10:133–138.
   PubMed Web of Science ®Google Scholar
• Heinrichs DW, Hanlon TE, Carpenter WT, Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388–398.
   PubMed Web of Science ®Google Scholar
• Auquier P, Simeoni MC, Sapin C, et al. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophr Res. 2003;63:137–149.
   PubMed Web of Science ®Google Scholar
• Wilkinson G, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177:42–46.
   PubMed Web of Science ®Google Scholar
• Isjanovski V, Naumovska A, Bonevski D, et al. Validation of the Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4) among patients with schizophrenia. Open Access Maced J Med Sci. 2016;4:65–69.
   PubMedGoogle Scholar
• Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321–326.
   PubMed Web of Science ®Google Scholar
• Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.
   PubMed Web of Science ®Google Scholar
• Montemagni C, Rocca P. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life [Review]. Neuropsych Dis Treat. 2016;12:917–929.
   PubMed Web of Science ®Google Scholar
• Rocca P, Montemagni C, Zappia S, et al. Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real world-setting. Psychiat Res. 2014;218:284–289.
   PubMed Web of Science ®Google Scholar
• Mazumder AH, Alam MT, Yoshii H, et al. Positive and negative symptoms in patients of schizophrenia: a cross sectional study. Acta Med Int. 2015;2:48–52.
   Google Scholar
• Karow A, Moritz S, Lambert M, et al. Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia [Research Support, Non-U.S. Gov't]. Eur Psychiat. 2012;27:401–405.
   PubMed Web of Science ®Google Scholar
• Dahlan R, Midin M, Shah SA, et al. Functional remission and employment among patients with schizophrenia in Malaysia. Compr Psychiat. 2014;55:S46–S51.
   PubMed Web of Science ®Google Scholar
• Chang LR, Lin YH, Chang HC, et al. Psychopathology, rehospitalization and quality of life among patients with schizophrenia under home care case management in Taiwan [Research Support, Non-U.S. Gov't]. J Formos Med Assoc. 2013;112:208–215.
   PubMed Web of Science ®Google Scholar
• Neto JH, Elkis H. Clinical aspects of super-refractory schizophrenia: a 6-month cohort observational study. Revista de Psiquiatria do Rio Grande do Sul. 2007;29:228–232.
   Google Scholar
• da Silva TFC, Mason V, Abelha L, et al. Quality of life assessment of patients with schizophrenic spectrum disorders from psychosocial care centers [Avaliacao da qualidade de vida dos pacientes com transtorno do espectro esquizofreico atendidos nos centros de atencao psicossocial na cidade do rio de janeiro.]. J Bras Psiquiatria. 2011;60:91–98.
   Google Scholar
• Wang XQ, Petrini MA, Morisky DE. Predictors of quality of life among Chinese people with schizophrenia. Nurs Health Sci. 2017;19:142–148.
   PubMed Web of Science ®Google Scholar
• Razali SM, Yusoff MZ. Medication adherence in schizophrenia: a comparison between outpatients and relapse cases [Comparative Study; Research Support, Non-U.S. Gov't]. East Asian Arch Psy. 2014;24:68–74.
   PubMedGoogle Scholar
• Rocca P, Montemagni C, Mingrone C, et al. A cluster-analytical approach toward real-world outcome in outpatients with stable schizophrenia. Eur Psychiat. 2016;32:48–54.
   PubMed Web of Science ®Google Scholar
• Glick HA, Li P, Harvey PD. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial. Schizophr Res. 2015;166:110–114.
   PubMed Web of Science ®Google Scholar
• Hong J, Windmeijer F, Novick D, et al. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study [Comparative Study; Multicenter Study; Research Support, Non-U.S. Gov't]. Prog Neuro-Psychopha. 2009;33:835–841.
   PubMed Web of Science ®Google Scholar
• Midin M, Razali R, ZamZam R, et al. Clinical and cognitive correlates of employment among patients with schizophrenia: a cross-sectional study in Malaysia. Int J Ment Health Sy. 2011;5 (no pagination)(14).
   Web of Science ®Google Scholar
• Sicras-Mainar A, Maurino J, Ruiz-Beato E, et al. Impact of negative symptoms on healthcare resource utilization and associated costs in adult outpatients with schizophrenia: a population-based study [Research Support, Non-U.S. Gov't]. BMC Psychiatry. 2014;14:225.
   PubMed Web of Science ®Google Scholar
• Mohr P, Rodriguez M, Bravermanova A, et al. Social and functional capacity of schizophrenia patients: a cross-sectional study. Int J Soc Psychiatr. 2014;60:352–358.
   PubMed Web of Science ®Google Scholar
• Lambert M, Naber D, Eich FX, et al. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride [Clinical Trial; Research Support, Non-U.S. Gov't]. Acta Psychiat Scand. 2007;115:106–113.
   PubMed Web of Science ®Google Scholar
• Gorwood P. Factors associated with hospitalisation of patients with schizophrenia in four European countries [Multicenter Study; Research Support, Non-U.S. Gov't]. Eur Psychiat. 2011;26:224–230.
   PubMed Web of Science ®Google Scholar
• Alessandrini M, Lancon C, Fond G, et al. A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. Schizophr Res. 2016;171:27–34.
   PubMed Web of Science ®Google Scholar
• Jager M, Weiser P, Becker T, et al. Identification of psychopathological course trajectories in schizophrenia [Multicenter Study; Ui - 52933903]. Psychiat Res. 2014;215:274–279.
   PubMed Web of Science ®Google Scholar
• Witte MM, Case MG, Schuh KJ, et al. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia [Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't]. Curr Med Res Opin. 2012;28:315–323.
   PubMed Web of Science ®Google Scholar
• Sarlon E, Heider D, Millier A, et al. A prospective study of health care resource utilisation and selected costs of schizophrenia in France [Research Support, Non-U.S. Gov't]. BMC Health Serv Res. 2012;12:269–276.
   PubMed Web of Science ®Google Scholar
• Siani C, de Peretti C, Millier A, et al. Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC [Multicenter Study]. Qual Life Res. 2016;25:925–934.
   PubMed Web of Science ®Google Scholar
• Mohamed S, Rosenheck R, Swartz M, et al. Relationship of cognition and psychopathology to functional impairment in schizophrenia [Randomized Controlled Trial; Research Support, N.I.H., Extramural]. Am J Psychiat. 2008;165:978–987.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Blanc O, Samalin L, et al. Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. Eur Psychiat. 2012;27:396–400.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Levine SZ, Garibaldi G, et al. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137:147–150.
   PubMed Web of Science ®Google Scholar
• Karve SJP, J. M, Dirani RG, Candrilli SD. Health care utilization and costs among medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Out Res Med. 2012;3:e183–e194.
   Google Scholar
• Boyer L, Millier A, Perthame E, Aballea S, Auquier P, Toumi M. Quality of life is predictive of relapse in schizophrenia [Multicenter Study; Research Support, Non-U.S. Gov't]. BMC Psychiatry. 2013;13:15.
   PubMedGoogle Scholar
• Bosia M, Marino E, Anselmetti S, et al. Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neurosci Lett. 2007;417:271–274.
   PubMed Web of Science ®Google Scholar
• Miyaji S, Yamamoto K, Morita N, et al. The relationship between patient characteristics and psychiatric day care outcomes in schizophrenic patients. Psychiat Clin Neuros. 2008;62:293–300.
   PubMed Web of Science ®Google Scholar
• Haro JM, Novick D, Perrin E, et al. Symptomatic remission and patient quality of life in an observational study of schizophrenia: Is there a relationship? Psychiat Res. 2014;220:163–169.
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108:223–230.
   PubMed Web of Science ®Google Scholar
• Potkin SG, Loze JY, Forray C, et al. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study. PLoS One. 2017;12 (no pagination)(e0183475).
   PubMed Web of Science ®Google Scholar
• Sarikaya Varlik DG, Uzun, UE, Varlik C, et al. Factors associated with re-hospitalizations in schizophrenia: a community mental health service research [Conference Abstract]. Eur Neuropsychopharm. 2015;2:S536–S537.
   Google Scholar
• Caqueo-Urizar A, Gutierrez-Maldonado J, Miranda-Castillo C. Quality of life in caregivers of patients with schizophrenia: a literature review. Health Qual Life Out. 2009;7:84.
   PubMed Web of Science ®Google Scholar
• Chong HY, Teoh SL, Wu DB, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373.
   PubMed Web of Science ®Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77:764–771.
   PubMed Web of Science ®Google Scholar
• Hawthorne WB, Folsom DP, Sommerfeld DH, et al. Incarceration among adults who are in the public mental health system: rates, risk factors, and short-term outcomes. Psychiatr Serv. 2012;63:26–32.
   PubMed Web of Science ®Google Scholar